Advertisement

Visceral osteopathic manipulative treatment reduces patient reported digestive toxicities induced by adjuvant chemotherapy in breast cancer: A randomized controlled clinical study

      Abstract

      Objective

      Breast cancer patients often benefit from adjuvant chemotherapy, a protocol whose effectiveness is accompanied by disabling adverse effects. The aim of this controlled clinical study was to determine the impact of visceral osteopathy on the incidence of nausea/vomiting, constipation and overall quality of life (QoL) in women operated for breast cancer and undergoing adjuvant chemotherapy in Centre Georges François Leclerc, CGFL.

      Study Design

      Ninety-four women operated for a breast cancer stage 1–3, in complete resection and to whom a 3 FEC 100 chemotherapy was prescribed, were randomly allocated to experimental or placebo group. Experimental group underwent a visceral osteopathic technique and placebo group was subjected to a superficial manipulation after each chemotherapy cycle. Rate of grade ≥1 nausea/vomiting or constipation, on the first 3 cycles of FEC 100, were reported. QoL was evaluated using the EORTC QLQ-C30 questionnaire.

      Results

      Rate of nausea/vomiting episodes of grade ≥1 was high in both experimental and placebo group. Constipation episodes of grade ≥1 were also frequent. No significant differences were found between the two groups concerning the rate of nausea/vomiting (p = 0.569) or constipation (p = 0.204) according to clinician reported side-effects but patient reported impact of constipation and diarrhoea on quality of life was significantly lower in experimental group (p = 0.036 and p = 0.038, respectively).

      Conclusion

      Osteopathy does not reduce the incidence of nausea/vomiting in women operated for breast cancer and undergoing adjuvant chemotherapy. In contrast, patient reported digestive quality of life was significantly ameliorated by osteopathy. Clinicaltrials.gov Identifier: NCT02840890.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      References

        • Bray F.
        • Ferlay J.
        • Soerjomataram I.
        • Siegel R.L.
        • Torre L.A.
        • Jemal A.
        Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
        CA Cancer J Clin. 2018; https://doi.org/10.3322/caac.21492
        • Bonneterre J.
        • Roché H.
        • Kerbrat P.
        • Fumoleau P.
        • Goudier M.-J.
        • Fargeot P.
        • et al.
        Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
        J Clin Oncol. 2004; 22: 3070-3079https://doi.org/10.1200/JCO.2004.03.098
      1. Comission de Transparence. Avis TAXOTERE (docétaxel).
        HAS- Direction de l’Evaluation Médicale, Economique et de Santé Publique, 2006
        • French Adjuvant Study Group
        Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial.
        J Clin Oncol Off J Am Soc Clin Oncol. 2001; 19: 602-611https://doi.org/10.1200/JCO.2001.19.3.602
        • Roché H.
        • Fumoleau P.
        • Spielmann M.
        • Canon J.-L.
        • Delozier T.
        • Serin D.
        • et al.
        Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial.
        J Clin Oncol. 2006; 24: 5664-5671https://doi.org/10.1200/JCO.2006.07.3916
      2. Comission de la transparence. Avis aprépitant.
        HAS- Direction de lEvaluation Médicale, Economique et de Santé Publique, 2016
        • Roila F.
        • Molassiotis A.
        • Herrstedt J.
        • Aapro M.
        • Gralla R.J.
        • Bruera E.
        • et al.
        MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients.
        Ann Oncol. 2016; 27: v119-33https://doi.org/10.1093/annonc/mdw270
        • Dibble S.L.
        • Chapman J.
        • Mack K.A.
        • Shih A.S.
        Acupressure for nausea: results of a pilot study.
        Oncol Nurs Forum. 2000; 27: 41-47
        • Billhult A.
        • Bergbom I.
        • Stener-Victorin E.
        Massage relieves nausea in women with breast cancer who are undergoing chemotherapy.
        J Altern Complement Med N Y N. 2007; 13: 53-57https://doi.org/10.1089/acm.2006.6049
        • Favier N.
        • Guinet A.
        • Nageleisen M.
        • Ceccaldi B.
        • Pujade-Lauraine É
        • LeFoll C.
        • et al.
        Évaluation de l’efficacité d’un traitement ostéopathique sur les effets secondaires et la qualité de vie de patients sous chimiothérapie Essai clinique multicentrique randomisé.
        2012: 8
        • Jarry G.
        • Meslé R.
        • Lehougre D.
        Ostéopathie et effets secondaires digestifs de la chimiothérapie.
        ApoStill. 2007; : 21-28
        • Aaronson N.K.
        • Ahmedzai S.
        • Bergman B.
        • Bullinger M.
        • Cull A.
        • Duez N.J.
        • et al.
        The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.
        J Natl Cancer Inst. 1993; 85: 365-376
        • National Cancer Institute (NCI)
        Common terminology criteria for adverse events (CTCAE) V.4.03.
        2010: 80
        • The CINV Study Group of Japan
        • Tamura K.
        • Aiba K.
        • Saeki T.
        • Nakanishi Y.
        • Kamura T.
        • et al.
        Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan.
        Int J Clin Oncol. 2017; 22: 405-412https://doi.org/10.1007/s10147-016-1069-7
        • Hesketh P.J.
        • Aapro M.
        • Street J.C.
        • Carides A.D.
        Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy.
        Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2010; 18: 1171-1177https://doi.org/10.1007/s00520-009-0737-9
        • Warr D.
        Prognostic factors for chemotherapy induced nausea and vomiting.
        Eur J Pharmacol. 2014; 722: 192-196https://doi.org/10.1016/j.ejphar.2013.10.015
        • Steel A.
        • Tricou C.
        • Monsarrat T.
        • Ruer M.
        • Deslandes C.
        • Sisoix C.
        • et al.
        The perceptions and experiences of osteopathic treatment among cancer patients in palliative care: a qualitative study.
        Support Care Cancer. 2018; 26: 3627-3633https://doi.org/10.1007/s00520-018-4233-y
        • Gibson R.J.
        • Keefe D.M.K.
        Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies.
        Support Care Cancer. 2006; 14: 890-900https://doi.org/10.1007/s00520-006-0040-y
        • Eisenberg P.
        • Figueroa-Vadillo J.
        • Zamora R.
        • Charu V.
        • Hajdenberg J.
        • Cartmell A.
        • et al.
        Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
        Cancer. 2003; 98: 2473-2482https://doi.org/10.1002/cncr.11817
      3. C. Cherwin, L. Nakad, A. Albashayreh. Systematic Review of Nonpharmacologic Approaches for the Management of Gastrointestinal Symptoms n.d.:21.

        • Belvaux A.
        • Bouchoucha M.
        • Benamouzig R.
        Osteopathic management of chronic constipation in women patients. Results of a pilot study.
        Clin Res Hepatol Gastroenterol. 2017; 41: 602-611https://doi.org/10.1016/j.clinre.2016.12.003
        • Brugman R.
        • Fitzgerald K.
        • Fryer G.
        The effect of osteopathic treatment on chronic constipation – a pilot study.
        Int J Osteopath Med. 2010; 13: 17-23https://doi.org/10.1016/j.ijosm.2009.10.002
        • Litwin M.S.
        • Lubeck D.P.
        • Henning J.M.
        • Carroll P.R.
        Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database.
        J Urol. 1998; 159: 1988-1992
        • Petersen M.A.
        • Larsen H.
        • Pedersen L.
        • Sonne N.
        • Groenvold M.
        Assessing health-related quality of life in palliative care: comparing patient and physician assessments.
        Eur J Cancer. 2006; 42: 1159-1166https://doi.org/10.1016/j.ejca.2006.01.032
        • Cirillo M.
        • Venturini M.
        • Ciccarelli L.
        • Coati F.
        • Bortolami O.
        • Verlato G.
        Clinician versus nurse symptom reporting using the National Cancer Institute-common Terminology Criteria for adverse events during chemotherapy: results of a comparison based on patient’s self-reported questionnaire.
        Ann Oncol Off J Eur Soc Med Oncol. 2009; 20: 1929-1935https://doi.org/10.1093/annonc/mdp287
        • Basch E.
        • Iasonos A.
        • McDonough T.
        • Barz A.
        • Culkin A.
        • Kris M.G.
        • et al.
        Patient versus clinician symptom reporting using the National Cancer institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study.
        Lancet Oncol. 2006; 7: 903-909https://doi.org/10.1016/S1470-2045(06)70910-X
        • Di Maio M.
        • Gallo C.
        • Leighl N.B.
        • Piccirillo M.C.
        • Daniele G.
        • Nuzzo F.
        • et al.
        Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials.
        J Clin Oncol. 2015; 33: 910-915https://doi.org/10.1200/JCO.2014.57.9334
        • Fromme E.K.
        • Eilers K.M.
        • Mori M.
        • Hsieh Y.-C.
        • Beer T.M.
        How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the quality-of-life questionnaire C30.
        J Clin Oncol. 2004; 22: 3485-3490https://doi.org/10.1200/JCO.2004.03.025
        • World Health Organisation
        World Health Organization.
        Benchmarks for training in osteopathy. 2010: 2010